SNP Rs688 Within the Low-density Lipoprotein Receptor (LDL-R) Gene Associates with HCV Susceptibility
Overview
Authors
Affiliations
Background & Aims: Despite high-risk behaviour, 10%-20% of HCV multiple exposed individuals remain uninfected (MEU), whilst the remainder become infected (MEI). We hypothesize that host factors play a role in HCV susceptibility. We aimed to identify polymorphisms in host genes that encode for proteins involved in viral entry: CD81, Scavenger receptor 1 (SR-1), Low-density lipoprotein receptor (LDL-R), Claudin-1 (CLDN1), Occludin (OCLN) and Niemann-Pick C1-like 1 (NPC1L1).
Methods: Multiple exposed infected and MEU from two observational cohorts were selected. From the MSM study of acute infection with HCV (MOSAIC), HIV-1 infected MEU cases (n = 30) and HIV-1 infected MEI controls (n = 32) were selected based on reported high-risk behaviour. From the Amsterdam Cohorts Studies (ACS) injecting drug users (IDU) cohort, MEU cases (n = 40) and MEI controls (n = 22) were selected who injected drugs for ≥2 years, in the nineties, when HCV incidence was high. Selected single nucleotide polymorphisms (SNPs) were determined by sequencing or SNP assays.
Results: No associations were found for SNPs within genes coding for CD81, SR-1, Claudin-1 or Occludin between the MEU and MEI individuals from either cohort. We did observe a significant association for rs688 within the LDL-R gene with HCV infection (OR: 0.41 P = 0.001), however, LDL cholesterol levels did not vary between individuals carrying the differential SNPs. Additionally, a marginal significant effect was found for rs217434 and rs2072183 (OR: 2.07 P = 0.032 and OR: 1.76 P = 0.039, respectively) within NPC1L1.
Conclusions: Our results demonstrate that the rs688 SNP within the LDL-R gene associates with HCV susceptibility through mucosal as well as intravenous exposure.
Li Z, Ji W, Dai B, Chen S, Wang F, Duan G BMC Infect Dis. 2024; 24(1):750.
PMID: 39075371 PMC: 11287834. DOI: 10.1186/s12879-024-09640-2.
Atreya M, Cvijanovich N, Fitzgerald J, Weiss S, Bigham M, Jain P Crit Care. 2023; 27(1):250.
PMID: 37365661 PMC: 10291783. DOI: 10.1186/s13054-023-04535-1.
Watkinson R, Looi K, Laing I, Cianferoni A, Kicic A Front Immunol. 2021; 12:773600.
PMID: 34912343 PMC: 8666438. DOI: 10.3389/fimmu.2021.773600.
Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity.
Zapatero-Belinchon F, Otjengerdes R, Sheldon J, Schulte B, Carriqui-Madronal B, Brogden G Cells. 2021; 10(7).
PMID: 34209751 PMC: 8303410. DOI: 10.3390/cells10071626.
Interleukin-6 polymorphisms in HCC patients chronically infected with HCV.
Adnan F, Khan N, Iqbal A, Ali I, Petruzziello A, Sabatino R Infect Agent Cancer. 2020; 15:21.
PMID: 32266003 PMC: 7114800. DOI: 10.1186/s13027-020-00285-9.